NanoViricides, Inc. (OTCMKTS:NNVC) Rises on Drug Updates
The FDA pronouncements make it or break it for pharmaceutical companies. And for NanoViricides, Inc. (OTCMKTS:NNVC) it is a day of making, topping a rising trend in the past week to $1.16. The ticker traded up 12% on Friday, on volumes above $720,000. The news was mostly expected, given that the dengue fever treatment was unique and would quite probably receive the orphan drug status, meaning it was singular and for a problem that is not widespread, thus not offering too much potential for sales. Still, NNVC will soon be sending out a rare and vital treatment. 
To go on with this therapy and other offers, NNVC seems quite well equipped: 
- $15.4 million cash
- $17.8 million total assets
- $7.7 million total liabilities
- $3.6 million quarterly net loss
- $36 million loss for 96 months
Another plus for this ticker is the lack of an overly-active, blatant promotion, beyond a free mention in the middle of July. So far, NNVC benefits from a series of press releases on the company’s development, which are rather fact-oriented, rather than hype pieces on the potential of the new drug. Still, in the longer run NNVC may disappoint with its deepening losses, unless it manages to significantly improve the earnings.
Like NNVC, Advanced Cell Technologies, Inc. (OTCBB:ACTC) is a semi-permanent fixture among the most actively traded biopharmaceutical companies. The company has enough speculative promises, but so far drifts sideways, still uncertain of a bigger trend, after a brief disappointment a few months back.
AP Pharma, Inc. (OTCBB:APPA) is in a similar bind, working to recover from negative news, but so far only achieving a slow trend.
Pharmaceutical tickers are usually abundant, and come with involved stories of upcoming earnings or revolutionary medical inventions. It is best to do your own research on such companies, since they differ in quality and subsequently in their levels of risk. But even the best were known to lose dramatically, such as Titan Pharmaceuticals, Inc. (OTCBB:TTNP), which wiped out 85% of its value in a day.
It is unknown if NNVC would easily vault new heights, or break down as investors absorb the news on the new drug. At least the company has not been touted in emails since the mention by BeaconEquity.com on July 18th. Still, it is best to decide independently on your time horizon before you take up this biopharmaceutical promise at face value.
